Modulation of the innate immune response during respiratory tract infections

  • M. J. Schultz
  • T. van der Poll
  • J. Kesecioglu
Conference paper


Both the growing number of immunocompromised patients susceptible to pneumonia, and the widespread use of antibiotics that has led to a rise of antibiotic resistance among microorganisms, have made the treatment of pneumonia more difficult. Hence, there is a need for novel therapeutic approaches for respiratory tract infections. Immunotherapy, aimed at modulating the immune response, may serve as an important adjuvant to antibiotic therapy in the treatment of infectious diseases. However, before immunomodulation can become a serious tool in the treatment of severe pneumonia, knowledge of the pulmonary host defense needs to increase.


Tumor Necrosis Factor Alpha Innate Immune Response Severe Pneumonia Pneumococcal Pneumonia Infectious Focus 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wichterman KA, Baue AE, Chaudry IH (1980) Sepsis and septic shock — a review of laboratory models and a proposal. J Surg Res 29:189–201PubMedCrossRefGoogle Scholar
  2. 2.
    Piper RD, Cook DJ, Bone RC, Sibbald WJ (1996) Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 24:2059–2070PubMedCrossRefGoogle Scholar
  3. 3.
    Deitch EA (1998) Animal models of sepsis and shock: a review and lessons learned. Shock 9:1–11PubMedCrossRefGoogle Scholar
  4. 4.
    Poll T van der, Deventer S J van (1999) Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 13:413–426PubMedCrossRefGoogle Scholar
  5. 5.
    Hinshaw LB, Beller-Todd BK, Archer LT, et al (1981) Effectiveness of steroid/antibiotic treatment in primates administered LD100 Escherichia coli. Ann Surg 194:51–56PubMedCrossRefGoogle Scholar
  6. 6.
    Tracey KJ, Fong Y, Hesse DG, et al (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662–664PubMedCrossRefGoogle Scholar
  7. 7.
    Marchant A, Bruyns C, Vandenabeele P, et al (1994) The protective role of interleukin-10 in endotoxin shock. Prog Clin Biol Res 388:417–423PubMedGoogle Scholar
  8. 8.
    Dehoux MS, Boutten A, Ostinelli J, et al (1994) Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 150:710–716PubMedCrossRefGoogle Scholar
  9. 9.
    Poll T van der, Keogh CV, Buurman WA, Lowry SF (1997) Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. Am J Respk Crit Care Med 155:603–608CrossRefGoogle Scholar
  10. 10.
    Takashima K, Tateda K, Matsumoto T, et al (1997) Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 65:257–260PubMedGoogle Scholar
  11. 11.
    Laichalk LL, Kunkel SL, Strieter RM, et al (1996) Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect Immun 64:5211–5218PubMedGoogle Scholar
  12. 12.
    Gosselin D, DeSanctis J, Boule M, et al (1995) Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection withPseudomonas aeruginosa. Infect Immun 63:3272–3278PubMedGoogle Scholar
  13. 13.
    Brieland JK, Remick DG, Freeman PT, et al (1995) In vivo regulation of replicative Legionella pneumophila lung infection by endogenous tumor necrosis factor alpha and nitric oxide. Infect Immun 63:3253–3258PubMedGoogle Scholar
  14. 14.
    Beutler B (1995) TNF, immunity and inflammatory disease: lessons of the past decade. J Invest Med 43:227–235Google Scholar
  15. 15.
    Le J, Vilcek J (1987) Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 56:234–248PubMedGoogle Scholar
  16. 16.
    Tan AM, Ferrante A, Goh DH, et al (1995) Activation of the neutrophil bactericidal activity for nontypable Haemophilus influenzae by tumor necrosis factor and lymphotoxin. Pediatr Res 37:155–159PubMedCrossRefGoogle Scholar
  17. 17.
    Oswald IP, Wynn TA, Sher A, James SL (1992) Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation. Proc Natl Acad Sci USA 89:8676–8680PubMedCrossRefGoogle Scholar
  18. 18.
    Huffnagle GB, Toews GB, Burdick MD, et al (1996) Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 157:4529–4536PubMedGoogle Scholar
  19. 19.
    Amura CR, Fontan PA, Sanjuan N et al (1995) Tumor necrosis factor alpha plus interleukin 1 beta treatment protects granulocytopenic mice from Pseudomonas aeruginosa lung infection: role of an unusual inflammatory response. APMIS 103:447–459PubMedCrossRefGoogle Scholar
  20. 20.
    Amura CR, Fontan PA, Sanjuan N, Sordelli DO (1994) The effect of treatment with interieukin-1 and tumor necrosis factor on Pseudomonas aeruginosa lung infection in a granulocytopenic mouse model. Clin Immunol Immunopathol 73:261–266PubMedCrossRefGoogle Scholar
  21. 21.
    Standiford TJ, Wilkowski JM, Sisson TH, et al (1999) Intrapulmonary tumor necrosis factor gene therapy increases bacterial clearance and survival in murine gram-negative pneumonia. Hum Gene Ther 10:899–909PubMedCrossRefGoogle Scholar
  22. 22.
    Rijneveld AW, Florquin S, Branger J, et al (2001) TNF-alpha compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J Immunol 167:5240–5246PubMedGoogle Scholar
  23. 23.
    Poll T van der, Marchant A, Keogh CV, et al (1996) Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 174:994–1000PubMedCrossRefGoogle Scholar
  24. 24.
    Greenberger MJ, Stricter RM, Kunkel SL, et al (1995) Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 155:722–729PubMedGoogle Scholar
  25. 25.
    Evans GF, Snyder YM, Butler LD, Zuckerman SH (1989) Differential expression of interleukin-1 and mmor necrosis factor in murine septic shock models. Circ Shock 29:279–290PubMedGoogle Scholar
  26. 26.
    Bagby GJ, Plessala KJ, Wilson LA, et al (1991) Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect Dis 163:83–88PubMedCrossRefGoogle Scholar
  27. 27.
    Zanetti G, Heumann D, Gerain J, et al (1992) Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopoly saccharide. J Immunol 148:1890–1897PubMedGoogle Scholar
  28. 28.
    The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis (1987) N Engl J Med 317:659–665CrossRefGoogle Scholar
  29. 29.
    Abraham E, Wunderink R, Silverman H, et al (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273:934–941PubMedCrossRefGoogle Scholar
  30. 30.
    Bone RC, Fisher CJ Jr, Clemmer TP, et al (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653–658PubMedCrossRefGoogle Scholar
  31. 31.
    Schultz MJ, Rijneveld AW, Speelman P, et al (2001) Endogenous interferon-gamma impairs bacterial clearance from lungs during Pseudomonas aeruginosa pneumonia. Eur Cytokine Netw 12:39–44PubMedGoogle Scholar
  32. 32.
    Schultz M, Rijneveld A, Florquin S, et al (2002) The role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol 282:285–290Google Scholar
  33. 33.
    Sawa T, Corry DB, Gropper MA et al (1997) IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J Immunol 159:2858–2866PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • M. J. Schultz
  • T. van der Poll
  • J. Kesecioglu

There are no affiliations available

Personalised recommendations